{"name":"Lumos Pharma","slug":"lumos-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2051000,"revenueGrowth":34.7,"grossMargin":0,"rdSpend":22096000,"netIncome":-34034000,"cash":35078000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9ZNnBXZlJNV0tFWF85T0w4TXV5N2VsM3BJdVZIN0p3M0JnU3EwejVRYnU0UlRlNjZuQWN0Y3BFSFpkYjJSQW5UWGJadlY2eERFVFVkSXdhRUNab1JablE?oc=5","date":"2026-04-03","type":"regulatory","source":"Bitget","summary":"Ascendis Pharma Faces Label-Expansion Catalyst as Market Weighs Execution Risk vs. TransCon hGH Promise - Bitget","headline":"Ascendis Pharma Faces Label-Expansion Catalyst as Market Weighs Execution Risk vs. TransCon hGH Promise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOWXlLSF9XLWJGZFBGLUwwQ2ZEQ09WU1FKd18tQkJJQkV6Q1prd2hLTzVTbGV4RFRNWThZcTFzR2hNbUxTV3hYaFVsd0pycXpJczRhVDdVb2RpWXdmQnlRQXVhaXlNV1hDcjYxVWN6dFU1RDV5S0ZDd01QRnQtenF6Umdn?oc=5","date":"2025-08-28","type":"regulatory","source":"pharmaphorum","summary":"Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira - pharmaphorum","headline":"Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxQVXNPSUY4T0R1b0tNQWlPTlM0ZFBjakg3Y0d3RjlPZGtCbWFzMlkyeE1ZSUdkakRHUjZIN0I3czBNQ3hweTVvNVNFdkRFMlZ0MWpOa1pfU2d6UTRlOGRzY1R1bjVKbmx1SUNaY2FScFZ6TGx0Um5SSjBrc0YwZ0VrNUZvNzBDeVA2S1F0dlNEbWVFRmczN2tjbGpDaEI5aXkxcmZXQk52U0xYVTVmR2l2SDRpMUNyNVFsYUNuS3pLMF9GLUlQLVZNRldRekhXeW84bmxLOVA1QzFQa1JCTEt0UW1URzZDMG9PM0NhdFBWYnFzeUwxaHItNXd0cE9fUGlfM1lLeVNTYUxfRTBUam1HcmZjY1I?oc=5","date":"2025-06-10","type":"pipeline","source":"PR Newswire","summary":"Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPZENZSGxBNEZFUFFmWTR1VGdwS2NUSUx0R2FDNnBlZHNIeDNacU15czJJTWoxc3NkQk9sV0E5emcweDN3c29McnQ4aThrcHBkNE1NVERxYmhPY25hUndrOVFDcVFOTUR2bUgtNzRlMFBOV1lvSkpjc21qUm5pZk90RVdBR3g2ZjZ4Z19nMUlWNzRVRnhxdlZXMHAtcF9BMUhMT1pyMDJZalVWcDJmWEFReFZhRTVVYlFUNTVVVi1kWlY5U1kzRmc?oc=5","date":"2024-12-13","type":"deal","source":"Wilson Sonsini","summary":"Wilson Sonsini Advises Lumos Pharma on Tender Offer and Merger with Double Point Ventures - Wilson Sonsini","headline":"Wilson Sonsini Advises Lumos Pharma on Tender Offer and Merger with Double Point Ventures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQVkhuZlFFYURzQ25LcS1wZzlfR1FjZXBYNHkwOGI4SW5CSUlfTU9IS2ZvS200elZiampPbXhGSVBJQ203WFRVMFRVSDRuTkRreXlpLUlaXy1sZXdfR1hxQkNaNzBzemJ5QzhITE8ta0ZnbVhoMVZIX3J6R25uMWRwSEw4RXdxMnM?oc=5","date":"2024-12-12","type":"pipeline","source":"Yahoo Finance","summary":"Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance","headline":"Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisi","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-11-21","type":"trial","source":"GlobeNewswire","summary":"Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 - GlobeNewswire","headline":"Updated Phase 2 OraGrowtH Data Presented at ESPE 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFAzeTlGb1VMTHZLcDFTeWM3MUREOGFnU1VqbElnNkFTNTlfMzh1b29lcm1ubzJ2MlljeTVXZVJTQnRvWEdPZUZXRUFDN1hVb0RZeGs2Tm1TZVNWRDlhb1JJUFpodDlFX3ItdXNDQ1Jnd3hVR2dIRktJ?oc=5","date":"2024-10-24","type":"deal","source":"Pharmaceutical Technology","summary":"DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology","headline":"DPV set to acquire Lumos Pharma for $38m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPSDI0NWowUm1ORDNUUzZ6Z0Vhek9zSmhKVUE2RVFGM2Z5ck1ZMWQ1c015eV9sMEtBZEJIOHJBaUhZNE5samp2ZWt1SDB0V1BnMXhuczdvVlZQWWJ4VGpFMGtKUGxZRDRzb2tJOWs5RzVwX1N1S3M2bDVvcnBMZXpHQm5BWXJQYVFYOWpV?oc=5","date":"2024-10-23","type":"deal","source":"Yahoo Finance","summary":"Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - Yahoo Finance","headline":"Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNRDY5aFlwQmFicmxrSkFYX0xhUzVwekgxZHRXTHhNZHhadjNGZl9zU1gzX054T21xVXBwZEgyRjBqU2pEbHBOMy05MU9Jak94bDVMdUFjQ3lZRGRteEJHSUp6N0psNkRRU3pOdkE5VmZxXzVkdndJdXdMajY4aFhuTnhDZnVFUHg2QWc2Wmc3TUgtb3ROel9JMng0X0ZRN09ZYUE?oc=5","date":"2024-09-23","type":"trial","source":"Contemporary Pediatrics","summary":"LUM-201 phase 2 data for PGHD with Andrew Dauber, MD, MMSc - Contemporary Pediatrics","headline":"LUM-201 phase 2 data for PGHD with Andrew Dauber, MD, MMSc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQVWdiS2s3eWUzVnhuem1lUklwMDVtRGFiNFZBcWN6bU9panJZalpKb0tTMjEwbFlXbFRmUTBfajVEWmJERkl2VDRxZllKbi1nUG9yZ3R2RDR6VXBUWE1BcUZOOHFqSWZDNU1mT2dfeXM4UGdtVmk3WWFGWFJpbmdNQ2l0eGx5dVdYeTkzT0dhZUl3WFFtVW0tUXExdkNDU05GYkkzZnNYTG5iRWpkbWJFWXVoald6R2E2OTlha2tySzFYVEtk?oc=5","date":"2023-11-08","type":"trial","source":"Fierce Biotech","summary":"Lumos stock jumps as phase 2 results bring first oral growth hormone drug closer to market - Fierce Biotech","headline":"Lumos stock jumps as phase 2 results bring first oral growth hormone drug closer to market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQeTh4NzVkY3RyWHowRkFXQ05nakEwREU5QkljNTJGbmszdzJyR0I0RDA3elRfVXVVTmpDMThIaW5lRDNRSkdFdkllcVhBWWxQT2xVMnZwWEFjX3V1TzBKcG1RdFIza041Nm1neWZXeV94TVQ3Q3VhS1lGQ2ZYbTI2M3RaMEt5dXZjOVpCMHZWQ2doV0lkQmV3Y29kdVRWOE1KSC1Ea2J1TGptR2tWRXFxODBxRER1RmhVU29EMGx5dw?oc=5","date":"2022-11-15","type":"pipeline","source":"Fierce Pharma","summary":"Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis - Fierce Pharma","headline":"Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVzdEb1hpbnpBNzJXblJMUVR6VXFwOXpxeE8yX2ZIeS1QbFc3M3R3dHQ2M1A4eW5selcwMGdpTHBFUnRXTUNJcXhMX24zdy1HVE9NbUZwNFZJSkRfUVhRSHVFaGJ2RkF4ZXEwYVBFMF9SZGtqYUVqd2JfT3dNS2ZLX2pGUXRTeXFvWlp5LURqVGFqbW1DSVpGVUxxbw?oc=5","date":"2019-10-01","type":"deal","source":"BioPharma Dive","summary":"NewLink’s two-decade run ends in reverse merger, layoffs - BioPharma Dive","headline":"NewLink’s two-decade run ends in reverse merger, layoffs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2051000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":2051000,"period":"2023-12-31"},{"value":1523000,"period":"2022-12-31"},{"value":230000,"period":"2021-12-31"},{"value":168000,"period":"2020-12-31"},{"value":936000,"period":"2019-12-31"},{"value":246000,"period":"2019-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":22096000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-34034000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":35078000,"cashHistory":[],"totalAssets":40638000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}